Ƶ

Guillain-Barré and COVID; Head-to-Head Alzheimer's Blood Tests; Fastball EEG

— News and commentary from the world of neurology and neuroscience

Ƶ MedicalToday
Brain scan images with NeuroBreak in the center.

One in five people with (GBS) had a preceding SARS-CoV-2 infection, but whether COVID-19 increased GBS risk wasn't clear. (Brain)

The was linked to better cognitive functioning in older adults with brain pathology, suggesting it may promote cognitive resilience. (Journal of Alzheimer's Disease)

Plasma assays using certain mass spectrometry methods performed better than most immunoassays in detecting brain in early Alzheimer's disease. (JAMA Neurology)

People with neurologic conditions were more likely to have elevated scores than the general U.S. population. (Neurology Clinical Practice)

Fastball, a to measure recognition memory, picked up small, subtle changes in brain waves when people remembered an image and discriminated Alzheimer's patients from healthy controls, a small study showed. (Brain)

Low-dose levetiracetam and spatial memory in Alzheimer's patients who had seizures or subclinical epileptiform activity. (JAMA Neurology)

Humana filed suit against Biogen, saying the drug company sought to boost sales of natalizumab (Tysabri), interferon beta-1a (Avonex) and dimethyl fumarate (Tecfidera) by patients with free sample drugs and then encouraging them to get Medicare benefits and illegally paying their copays. (Bloomberg)

Verdiperstat, an investigational myeloperoxidase enzyme inhibitor, did not statistically differentiate from placebo on the primary efficacy measure or key secondary measures in a phase III trial of , Biohaven said.

  • Judy George covers neurology and neuroscience news for Ƶ, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.